Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

被引：0
|
作者：
Harrison, Claire [1 ]
Lord-Bessen, Jennifer [2 ]
Shi, Ling [3 ]
Guo, Shien [3 ]
Yucel, Aylin [2 ]
Zissler, Dorothy [2 ]
Jones, Shalon [2 ]
Slaff, Samantha [2 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, London, England
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Evidera, Bethesda, MD USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6624 / 6625
页数：2
相关论文
共 50 条
  • [41] Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.
    Tap, William D.
    Bhadri, Vivek
    Stacchiotti, Silvia
    Bauer, Sebastian
    Wagner, Andrew J.
    van de Sande, Michiel
    Bernthal, Nicholas M.
    Pousa, Antonio Lopez
    Razak, Albiruni Ryan Abdul
    Italiano, Antoine
    Ahmed, Mahbubl
    Le Cesne, Axel
    Tait, Christopher
    Zarins, Fiona
    Harrow, Brooke
    Sharma, Maitreyi G.
    Ruiz-Soto, Rodrigo
    Sherman, Matthew L.
    Blay, Jean-Yves
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
    Cella, David
    Gruenwald, Viktor
    Escudier, Bernard
    Hammers, Hans J.
    George, Saby
    Nathan, Paul
    Grimm, Marc-Oliver
    Rini, Brian, I
    Doan, Justin
    Ivanescu, Cristina
    Paty, Jean
    Mekan, Sabeen
    Motzer, Robert J.
    LANCET ONCOLOGY, 2019, 20 (02): : 297 - 310
  • [43] Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    Su, Yun
    Jabbour, Elias J.
    Bhattacharyya, Helen
    Yan, Eric
    Cappelleri, Joseph C.
    Marks, David I.
    CANCER, 2018, 124 (10) : 2151 - 2160
  • [44] ASSESSMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA): RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL
    Younossi, Zobair M.
    Stepanova, Maria
    Nader, Fatema
    Loomba, Rohit
    Anstee, Quentin M.
    Ratziu, Vlad
    Harrison, Stephen A.
    Sanyal, Arun J.
    Trotter, James F.
    Sheikh, Muhammad Y.
    Montano-Loza, Aldo J.
    Olveria, Antonio
    Stinton, Laura M.
    Sheridan, David A.
    Vargas, Victor
    Gluud, Lise L.
    Safadi, Rifaat
    Schattenberg, Joern
    Khalili, Mandana
    Orr, David W.
    Peck-Radosavljevic, Markus
    Allison, Michael E.
    Cawkwell, Gail
    Wong, Bruce
    Bedossa, Pierre
    Goodman, Zachary D.
    Rinella, Mary E.
    HEPATOLOGY, 2019, 70 : 1366A - 1368A
  • [45] Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial
    Bachert, Claus
    Hellings, Peter
    Mullol, Joaquim
    Hamilos, Daniel
    Naclerio, Robert
    Joish, Vijay N.
    Mannent, Leda
    Evans, Robert E.
    Grabher, Annette
    Abbe, Adeline
    Amand, Caroline
    Taniou, Christine
    Zhang, Donghui
    Fan, Chunpeng
    Pirozzi, Gianluca
    Graham, Neil
    Mastey, Vera
    Mahajan, Puneet
    Staudinger, Heribert
    Eckert, Laurent
    Khan, Asif
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [46] EFFECT OF WITHDRAWING ETANERCEPT OR METHOTREXATE ON PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION ON COMBINATION THERAPY: RESULTS FROM THE SEAM-RA TRIAL
    Curtis, J.
    Karis, E.
    Bykerk, V.
    Kricorian, G.
    Yen, P.
    Emery, P.
    Haraoui, P.
    Collier, D.
    Stolshek, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 66 - 66
  • [47] Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial
    Baraliakos, Xenofon
    Bessette, Louis
    Salvarani, Carlo
    Chen, Naijun
    Lippe, Ralph
    Patel, Jayeshkumar
    Song, In-Ho
    Zueger, Patrick
    Goupille, Philippe
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1517 - 1520
  • [48] Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
    Strand, Vibeke
    Mease, Philip
    Soriano, Enrique
    Kishimoto, Mitsumasa
    Salvarani, Carlo
    Damjanov, Nemanja
    Anderson, Jaclyn K.
    Blondell, Erin
    Zueger, Patrick
    Saffore, Christopher
    Gladman, Dafna
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [49] Improvement in Patient-Reported Outcomes in Patients With Psoriatic Arthritis With Inadequate Response to Non-Biologic DMARDs Treated With Upadacitinib Versus Placebo or Adalimumab: Results From a Phase 3 Study
    Gladman, Dafna
    Mease, Philip
    Soriano, Enrique
    Kishimoto, Mitsumasa
    Salvarani, Carlo
    Damjanov, Nemanja
    Anderson, Jaclyn
    Blondell, Erin
    Zueger, Patrick
    Saffore, Christopher
    Strand, Vibeke
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1168 - 1168
  • [50] Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required Red Blood Cell Transfusions: Subgroup Analysis of the Phase 3 SIMPLIFY-2 Study
    Harrison, Claire
    Scheid, Christoph
    Vannucchi, Alessandro M.
    Recher, Christian
    Passamonti, Francesco
    Gerds, Aaron T.
    Hernandez-Boluda, Juan Carlos
    Yacoub, Abdulraheem
    Sirhan, Shireen
    Kawashima, Jun
    Patel, Bharat
    Strouse, Bryan
    Platzbecker, Uwe
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 118
12345